BiotechTube

PEGASYS + Hydroxyurea + Aspirin

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

High Risk Polycythemia Vera

Conditions

High Risk Polycythemia Vera, High Risk Essential Thrombocythemia

Trial Timeline

Sep 1, 2011 → Jun 30, 2017

NCT ID
NCT01259856

About PEGASYS + Hydroxyurea + Aspirin

PEGASYS + Hydroxyurea + Aspirin is a phase 3 stage product being developed by Roche for High Risk Polycythemia Vera. The current trial status is completed. This product is registered under clinical trial identifier NCT01259856. Target conditions include High Risk Polycythemia Vera, High Risk Essential Thrombocythemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01259856Phase 3Completed

Competing Products

20 competing products in High Risk Polycythemia Vera

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
44
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
33
Sepantronium BromideCothera BiosciencePhase 2
44
Edoxaban + ASADaiichi SankyoPhase 3
77
olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
77
Bunazosin + Doxazosin + ValsartinEisaiApproved
85
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
33
DSP-0390Sumitomo PharmaPhase 1
33
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
33
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
77
SHR3680 + PlaceboJiangsu Hengrui MedicinePhase 3
77
Camrelizumab、Rivoceranib + CamrelizumabJiangsu Hengrui MedicinePhase 2
52
Mirvetuximab soravtansine + CarboplatinAbbViePhase 2
52
HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
77
Mirvetuximab SoravtansineAbbViePhase 2
52
Zibotentan/Dapagliflozin + DapagliflozinAstraZenecaPhase 2
52
AZD5718 IR tablet + AZD5718 oral suspension + Rosuvastatin tabletAstraZenecaPhase 1
33
Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3
77
Olaparib Pill + AZD6738AstraZenecaPhase 2
52
DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3
77

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85